Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
暂无分享,去创建一个
N. Vermeulen | B. V. van Vugt-Lussenburg | J. Commandeur | J. D. de Vlieger | Jon S. B. de Vlieger | M. Damsten | Tineke Zeldenthuis
[1] Dominic P. Williams,et al. Metabolism and bioactivation of clozapine by human liver in vitro. , 1995, The Journal of pharmacology and experimental therapeutics.
[2] F. Guengerich,et al. Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. , 1993, Archives of biochemistry and biophysics.
[3] Y. Masubuchi,et al. Mechanism-based inactivation of CYP2C11 by diclofenac. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[4] Dominic P. Williams,et al. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. , 1995, The Journal of pharmacology and experimental therapeutics.
[5] Christian Skonberg,et al. Development and evaluation of an electrochemical method for studying reactive phase-I metabolites: correlation to in vitro drug metabolism. , 2007, Chemical research in toxicology.
[6] T. Baillie,et al. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. , 2006, Chemical research in toxicology.
[7] Zhengyin Yan,et al. DETECTION OF A NOVEL REACTIVE METABOLITE OF DICLOFENAC: EVIDENCE FOR CYP2C9-MEDIATED BIOACTIVATION VIA ARENE OXIDES , 2005, Drug Metabolism and Disposition.
[8] K. Ishak,et al. Diclofenac‐associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions , 1995, Hepatology.
[9] K. Albert,et al. Isolation and identification of clozapine metabolites in patient urine. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[10] N. Vermeulen,et al. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. , 2007, Journal of medicinal chemistry.
[11] N. Vermeulen,et al. Rat liver microsomal cytochrome P450-dependent oxidation of 3,5-disubstituted analogues of paracetamol. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[12] Gary W Caldwell,et al. Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. , 2004, Analytical chemistry.
[13] K. R. Marshall,et al. P450 BM3: the very model of a modern flavocytochrome. , 2002, Trends in biochemical sciences.
[14] M. Olkinuora,et al. Agranulocytosis during treatment with clozapine , 1977, European Journal of Clinical Pharmacology.
[15] T. Leemann,et al. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.
[16] S. Nelson,et al. Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[17] Yue Chen,et al. IDENTIFICATION OF A NOVEL GLUTATHIONE ADDUCT OF DICLOFENAC, 4′-HYDROXY-2′-GLUTATHION-DESCHLORO-DICLOFENAC, UPON INCUBATION WITH HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.
[18] E. Björnsson,et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden , 2005, Scandinavian Journal of Gastroenterology.
[19] T. Baillie,et al. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. , 1999, Chemical research in toxicology.
[20] N. Vermeulen,et al. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. , 2006, Biochemical and biophysical research communications.
[21] K. Midha,et al. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. , 1999, Chemico-biological interactions.
[22] T. Baillie,et al. Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[23] T. Baillie,et al. Mass spectrometry in the analysis of glutathione conjugates. , 1993, Biological Mass Spectrometry.
[24] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[25] F. Guengerich,et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. , 1993, Chemical research in toxicology.
[26] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[27] M. Davis,et al. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. , 1999, Chemical research in toxicology.
[28] Zhengyin Yan,et al. Screening for reactive intermediates and toxicity assessment in drug discovery. , 2006, Current opinion in drug discovery & development.
[29] C. Hobbs,et al. New cloning vectors and techniques for easy and rapid restriction mapping. , 1988, Gene.
[30] N. Vermeulen,et al. Paracetamol (Acetaminophen)-Induced Toxicity: Molecular and Biochemical Mechanisms, Analogues and Protective Approaches , 2001, Critical reviews in toxicology.
[31] C. W. Fisher,et al. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. , 1999, Mutation research.
[32] V. Urlacher,et al. Immobilisation of P450 BM‐3 and an NADP+ Cofactor Recycling System: Towards a Technical Application of Heme‐Containing Monooxygenases in Fine Chemical Synthesis , 2003 .